Across TCGA pan-cancer cohorts, SLC38A3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC38A3 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SLC38A3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC38A3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC, UCEC, and BLCA are the cancer types where SLC38A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	1.000	0.267	.026	5	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SLC38A3 tumor-vs-normal RNA expression · all SLC38A3 data types